Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hoth Therapeutics ( (HOTH) ) has provided an update.
On August 5, 2025, Hoth Therapeutics held its annual shareholder meeting where key decisions were made, including the re-election of board members and the ratification of Withum Smith+Brown as the independent accounting firm for 2025. Additionally, shareholders approved an amendment to the 2022 Omnibus Equity Incentive Plan to increase the reserved shares for issuance, and advisory votes on executive compensation were conducted.
The most recent analyst rating on (HOTH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for dermatological and immunological conditions.
Average Trading Volume: 1,173,135
Technical Sentiment Signal: Buy
Current Market Cap: $17.24M
For detailed information about HOTH stock, go to TipRanks’ Stock Analysis page.